Sunday ScariesJune 14, 2026

Vol. 8 · Week of June 14, 2026

Sunday Scaries Vol. 8

SpaceX priced the largest IPO ever and jumped 19% on debut, with Goldman taking lead-left. CPI reignited to 4.2% and the ECB hiked for the first time since 2023. Plus GSK's $10.6B oncology buy. Five-minute recap before Monday.

The SpaceX IPO we flagged when it filed last month actually priced this week, and it did not disappoint: the largest deal on record, up 19% on day one, with Goldman grabbing the lead-left slot Morgan Stanley held at filing. The same week, inflation came back hot enough to put the rate-cut story back in doubt, the ECB hiked for the first time since 2023, and GSK paid up for precision oncology. Plus a recruiting squeeze with one very loud exception. Five minutes, every section, ammo for Monday.

Top Stories of the Week

1. SpaceX priced the largest IPO in history, and Goldman won the slot that matters.

SpaceX priced at $135 a share on June 11, raised $75 billion, and opened on Nasdaq under SPCX the next day at a $1.77 trillion valuation, the biggest IPO ever by a wide margin. Shares closed up 19% at $161 on day one. The part bankers care about is the league-table win. When SpaceX filed in May, Morgan Stanley sat left-lead. By pricing, Goldman Sachs had taken the lead-left slot on a 23-bank syndicate, with Morgan Stanley pivoting to run an unusually large retail tranche (roughly 30% of shares went to retail through E*Trade, Schwab, Fidelity, Robinhood, and SoFi, about triple the usual allocation). Total underwriting fees ran near $500 million. And the pipeline behind it is the real story: Anthropic and OpenAI both filed confidential S-1s within the same week, part of what Bloomberg is calling a $3.6 trillion AI IPO wave queued up for a single year.

Why you care: This is the defining capital-markets event of the decade. Goldman's lead-left win will anchor ECM league tables for 2026 and frame the Goldman-versus-Morgan-Stanley story in recruiting conversations well into 2027. If you are targeting ECM or a top bulge bracket, you need a point of view on it.

Interview angle: "The tell is the 0.75% gross spread, the lowest on record for a conventional IPO. Goldman did not win by charging the most. It controlled institutional allocation, and the soft-dollar economics from that more than paid for the thin fee. That makes lead-left a franchise play, not a fee play."

2. Inflation came back hot, the ECB hiked, and Warsh runs his first meeting Tuesday.

May CPI printed at 4.2% year over year on June 10, the hottest since April 2023, driven by a 3.9% monthly jump in energy as the Iran conflict squeezed oil flows through the Strait of Hormuz. The cleaner read is underneath the headline: core CPI held at 2.9%, which says the domestic demand picture is more contained than the top-line number suggests. The ECB moved first, hiking 25 basis points to 2.25% on June 11, its first hike since 2023, while cutting its 2026 eurozone growth forecast to 0.8%. Kevin Warsh chairs his first FOMC meeting June 16 and 17, with markets pricing better than 99% odds of a hold at 3.50 to 3.75%. He has signaled he wants less forward guidance and fewer press conferences than his predecessor, which means more meeting-to-meeting uncertainty about where rates head next.

Why you care: Energy-driven headline inflation muddies the rate-cut story a lot of 2026 deal models were built on. LBO structures penciled in on two Fed cuts this year are getting stress-tested right now. The distinction interviewers want to hear is exogenous supply-shock inflation (energy, Iran) versus demand-driven inflation the Fed can actually control, because that is exactly the call deal committees are making.

Interview angle: "The risk to frame is stagflation. If Iran keeps energy elevated, the Fed is stuck between cutting to support growth and holding to fight inflation. That combination suppresses deal activity and raises portfolio-company operating costs at the same time, which is the worst setup for a sponsor."

3. GSK paid $10.6B for Nuvalent, and precision-oncology M&A is back.

GSK agreed on June 9 to buy Nasdaq-listed Nuvalent for $10.6 billion in all cash at $124 a share, about a 40% premium to recent trading. It is GSK's largest acquisition in more than a decade and its third material deal of 2026. The prize is Nuvalent's late-stage precision-oncology pipeline: zidesamtinib, a ROS1 inhibitor already under FDA review, and neladalkib, an ALK inhibitor in Phase 3, both targeting non-small cell lung cancer, with combined peak revenue analysts estimate near $823 million. Centerview and Jefferies advised Nuvalent; Leerink and Citi ran buy-side for GSK. Close is expected in the third quarter.

Why you care: This is the textbook large-cap pharma bolt-on: public target, premium to market, two FDA-stage assets. Healthcare coverage and leveraged finance are both busy in 2026, and walking in with a live deal you can speak to on specifics beats reciting one from last year.

Interview angle: "Use the 40% premium to talk precedent transactions in healthcare. First-in-class oncology mechanisms with FDA-stage data usually clear 35 to 50% premiums, and whether a competing bidder shows up is what moves you within that band."

Deals of the Week

Ingredion is buying the UK's Tate & Lyle for £3.7B in a recommended all-cash deal. Announced June 8 at a 59% premium, the deal carries a £3.7 billion ($5.0 billion) enterprise value and £2.7 billion ($3.6 billion) of equity value, funded with a $4.23 billion bridge loan and targeting $130 million of synergies by 2030. It is about as clean a model for a UK public take-private as you will find this year: cross-border (U.S. buyer, London-listed target), board-recommended, with a full advisor matrix on both sides.

Buy-side (Ingredion): J.P. Morgan Securities (financial); Hogan Lovells (legal)
Sell-side (Tate & Lyle): Goldman Sachs International and Greenhill & Co. (joint lead financial); BofA Securities and Citigroup (joint advisors and corporate brokers); Linklaters (legal)

Dana and Eaton are combining Eaton's mobility business in a $5.1B Reverse Morris Trust. Announced June 11. The structure is the whole lesson here: a Reverse Morris Trust lets a parent spin off a division and merge it into another company tax-free, as long as the parent's own shareholders end up owning more than half of the combined entity. Goldman ran it as sole advisor to Dana. Worth reading closely, because the structure shows up in interviews far more than it shows up in deals.

Dana advisors: Goldman Sachs, exclusive (financial); Kirkland & Ellis (legal)
Eaton advisors: Not disclosed

Pro tip: The Reverse Morris Trust is your structure to know cold this week. The setup: a parent wants to offload a division without paying corporate tax on the gain, so instead of selling it for cash, it spins the division out to its own shareholders and immediately merges it with a partner company. As long as the parent's shareholders own more than 50% of the combined business, the IRS treats the whole thing as tax-free. That is the catch most candidates miss: the merger partner has to be small enough that the seller's holders stay in control. Explain why, and you understand the RMT better than most first-years.

Recruiting Pulse

Analyst classes are shrinking, and one bank is betting loudly the other way. Recent grads and analysts we hear from describe materially smaller 2026 classes than two years ago, and the reporting backs it up: Fortune put the cuts as high as two-thirds across the street, with banks pointing straight at AI for automating the first-year grind of comps, document drafting, and first-pass models. The loud exception is Bank of America. On June 3 it said it is hiring 2,000 summer interns and 2,000 full-time campus recruits across all eight business lines, and framed the move as a bet that judgment and client relationships are the parts AI cannot replace. The takeaway for this cycle: fewer seats overall, and they cluster at the banks willing to make a counter-cyclical hire.

Goldman's SpaceX win is already rewriting "Why Goldman?" answers. Analysts on Goldman's ECM desk tell us the SpaceX mandate is getting passed around internally as the case study in franchise-first deal strategy: Goldman reportedly bid the lowest underwriting fee in the syndicate to win lead-left, then earned multiples of it through institutional allocation. If you are interviewing at Goldman this cycle, articulating that trade-off, with SpaceX as the live example, is landing in final rounds. The one-liner to internalize: Goldman does not win mandates by being the cheapest. It wins by being the bank clients call when the deal has to go right.

What's New on Superday AI

Three things worth your time this week:

The Whiteboard got a major upgrade.

Lessons get drawn onto the board in real time, narrated out loud with captions that keep you on pace, so any concept builds step by step instead of sitting on a slide. Raise your hand mid-lesson and it works your question out live. We also reworked Concept Drills with a dedicated review queue that brings your missed questions back around, plus sharper, more specific feedback on every answer.

Open the Whiteboard

Rehearse your "Why this bank?" answer against an interviewer that pushes back.

"Why Goldman" or "Why this group" is where strong candidates separate from merely prepared ones, and you cannot wing it the first time you say it live. Our AI mocks run a real back-and-forth, adapt to your answers, and throw the follow-up an actual interviewer would. Walk in having already taken the awkward hit in practice instead of in the room.

Start a mock

AI-Powered Interview Prep

Want this in your inbox every Sunday?

Free. Five minutes. Built for college students who want the IB news that actually moves recruiting forward.

Start Free Practice View Pricing

More Sunday Scaries

Vol. 7 · June 7, 2026

Sunday Scaries Vol. 7: Week of June 7, 2026

Vol. 6 · May 31, 2026

Sunday Scaries Vol. 6: Week of May 31, 2026

Vol. 5 · May 24, 2026

Sunday Scaries Vol. 5: Week of May 24, 2026

All Volumes Read the Blog